Skip to content
Search

Latest Stories

RPS and Pharmacist Support host roundtable to explore actions needed to support staff

The Royal Pharmaceutical Society (RPS) and Pharmacist Support hosted a roundtable on the impact of pharmacy workforce wellbeing on patient safety on Wednesday (17 May).

It also released its annual Workforce Wellbeing Survey which showed continued pressures on pharmacy teams.


The discussion explored the actions needed to support staff so they can continue providing safe and effective patient care and included representatives from the NHS, professional bodies, employers, trade unions, education and regulators.

A report of the roundtable will be published in the summer.

Amandeep Doll, RPS Head of Professional Belonging, said: “We know that pharmacy teams go above and beyond for their patients, but are also under enormous pressure.

“Now more than ever, we need to strive to make the pharmacy profession more inclusive and ensure that everyone’s wellbeing is supported.

“It is vital that we do all we can to encourage people into pharmacy and to support them so they can enhance their skills, develop their careers, and continue to deliver high-quality patient care.

“This discussion was a welcome step and showed that making a difference for staff wellbeing requires a concerted effort from stakeholders across the whole of pharmacy.

“RPS will produce a report of the discussion and as a group we have committed to meeting again in six months.”

In a joint statement RPS commented: “Pharmacy organisations, regulators, unions and employers heard about the well recognised correlations between the wellness and wellbeing of students, academics and the clinical workforce and the impact that this has on workforce effectiveness, patient safety and patient outcomes.

With continued pressure on pharmacy teams and the health service, it is more important than ever to work together so that patients can continue to access to high-quality, adequately staffed and safe pharmacy services.

Prioritising staff wellbeing and leadership within systems supports higher-quality and safer patient care and improves workforce retention.

The collaborative roundtable discussion highlighted the importance of supporting pharmacy teams across all sectors of practice to deliver patient care through healthy working environments, access to appropriate rest breaks, and opportunities for professional development.

Staff should feel empowered to use their professional judgement in the interests of patients and the public. Staff must also be given the support, training, and supervision they need to help enable them to complete their professional duties.

Solutions to the challenges facing workforce well-being require interventions that go beyond the individual. Making the health service a better place to work must be a shared endeavour so that we can continue to meet the needs of our patients and support our pharmacy people.”

The statement was supported by Association of Pharmacy Technicians, UK (APTUK); British Pharmaceutical Students Association (BPSA);  Care Quality Commission (CQC);  General Pharmaceutical Council (GPhC); Guild of Healthcare Pharmacists (GHP); National Pharmacy Association (NPA); Pharmacists Defence Association (PDA); Pharmacy School Council (PhSC); Community Pharmacy England (CPE); Pharmacist Support; and Royal Pharmaceutical Society (RPS).

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less